B7-1 Recombinant Protein Cat. No.: 96-791

Availability: In stock

$0.00

 Price Options

$0.00
psi-iconSpecifications
SPECIES:Cynomolgus, Rhesus macaque
SOURCE SPECIES:HEK293 cells
SEQUENCE:Val 35 - Asn 242
FUSION TAG:Fc Tag
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:This recombinant protein can be used for E, WB. For research use only.
BIOLOGICAL ACTIVITY: Measured by its binding ability in a functional ELISA. Immobilized Cynomolgus / Rhesus macaque CTLA-4, His Tag at 2 ug/mL (100 uL/well) can bind Cynomolgus / Rhesus macaque B7-1, Fc Tag with a linear range of 1-8 ng/mL (QC tested).
psi-iconProperties
PURITY:>95% as determined by reduced SDS-PAGE.

Less than 1.0 EU per μg by the LAL method.
PREDICTED MOLECULAR WEIGHT:50.5 kDa
PHYSICAL STATE:Lyophilized
BUFFER:Tris with Glycine, Arginine and NaCl, pH7.5
STORAGE CONDITIONS:Lyophilized Protein should be stored at -20˚C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20˚C or -70˚C. Avoid repeated freeze-thaw cycles.
psi-iconAdditional Info
ALTERNATE NAMES:CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7
ACCESSION NO.:G7NXN7
OFFICIAL SYMBOL:B7-1
GENE ID:102140078
psi-iconBackground and References
BACKGROUND:B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-kappaB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.
REFERENCES:1) Peach RJ., et al., 1995, J. Biol. Chem. (UNITED STATES) 270 (36): 21181–7.
2) Stamper CC., et al., 2001, Nature (England) 410 (6828): 608–11.
3) Bhatia S., et al., 2005, Proc. Natl. Acad. Sci. 102: 15569-15574.
4) Khan N., et al., 2007, Int. Immunol. 19:477-486.

FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.